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Abstract 
Background: Antimicrobial Resistance of 
Multidrug Resistant (MDR) Acinetobacter and 
Pseudomonas against Polymyxin E and Tigecycline 
is increasing exponentially. However, a wide range 
of susceptibility profiles to these drugs have been 
noted in different parts of the world. 
Objective: To determine the antimicrobial 
susceptibility of MDR Acinetobacter and 
Pseudomonas against Polymyxin E and Tigecycline.  
Materials & Methods: This cross-sectional 
study was conducted in Medical Intensive Care 
Units (MICU) of Holy Family Hospital for a 
duration of 1 year after ethical approval from 
Institutional Research Forum (IRF) of Rawalpindi 
Medical University. Hospital records of patients 
admitted in MICU were included using consecutive 
sampling technique. Organisms that were not MDR 
Acinetobacter or MDR Pseudomonas were 
excluded. Antimicrobial resistance of included 
isolates was noted against Polymyxin E & 
Tigecycline. Variables like gender, age, organism, 
site of isolation and antimicrobial resistance against 
Polymyxin E & Tigecycline were noted. Data was 
entered and analyzed using SPSS v20. 
Results: Mean age of isolation of MDR 
Acinetobacter was 35.79±15.55 years while mean age 
of isolation of MDR Pseudomonas was 26.54±7.83 
years. The difference was very highly statistically 
significant. MDR Acinetobacter & MDR 
Pseudomonas both were more commonly isolated 
from male as compared to female patients. MDR 
Acinetobacter & MDR Pseudomonas were most 
commonly isolated from catheter tips, followed by 
blood. However, MDR Pseudomonas was not 
isolated from urine. Antimicrobial resistance 
against Polymyxin E & Tigecycline was surprisingly 
high. 
Conclusion: The antimicrobial resistance of MDR 
Acinetobacter or MDR Pseudomonas was 
alarmingly high. Therefore, proper strategies 
should be formulated regarding use of 
antimicrobial agents. 
Keywords: Antimicrobial Resistance, 
Acinetobacter, Pseudomonas, MDR, Polymyxin E, 
Tigecycline 
 
Introduction 
One of the most common cause of morbidity & 
mortality in patients of Intensive Care Units is 
infection.1 Acinetobacter and Pseudomonas are one of 
the most prevalent infectious agents in ICUs and their 
association with higher mortality rate in infected 
patients has also been reported.2  
The concerning feature regarding Acinetobacter is its 
ability to develop antimicrobial resistance rapidly 
therefore an increasing trend in development of 
multidrug resistance has been observed. 3 
SENTRY surveillance program identified that 3.3% 
Multi Drug Resistant strains of Pseudomonas and 
3.2% Multi Drug Resistant strains of Acinetobacter 
isolated worldwide were resistant to Polymyxins. The 
resistance rate against Polymyxins was reported to be 
higher in Asia-Pacific region than other regions of the 
world.4 
In a study conducted in 17 tertiary-care hospitals in 
the area of Athens to determine in vitro efficacy of 
Tigecycline and Colistin against MDR strains of 
Acinetobacter it was found that 1% and 3% strains 
were resistant to these drugs respectively.5 
The ability of these organisms to have a long-term 
survival in hospital environment and association with 
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outbreaks of nosocomial infections including 
bacteremia, meningitis, pneumonia, UTIs and wound 
infections has also been reported.6 
Major risk factors associated with Acinetobacter 
infection are post-surgical, diabetes, IV 
catheterization, extended hospital stay and 
mechanical ventilation making Intensive Care Units 
one of the favorite environments for this organism. 
More than 40% strains of Acinetobacter have been 
reported to be resistant to  
carbepenams, aminoglycosides and fluoroquinolones 
while 100% resistance against penicillins & 
cephalosporins has been reported.7 In a study 
conducted at 2 tertiary care hospitals in Baltimore the 
hospital mortality rates for patients with MDR 
Acinetobacter infections (26%) were higher than for 
susceptible references (18%) and uninfected 
references (11%).8 
While Pseudomonas is one of the most commonly 
isolated organisms from patients with nosocomial 
pneumonia,9 it is becoming difficult to treat owing to 
the limited choice for antimicrobial agents due to 
very high resistance in MDR strains.10 
In a comparison of clinical outcomes in patients with 
MDR Pseudomonas and susceptible strains of 
Pseudomonas, the resistant strains have been 
attributed with 2 times more increase in mortality 
rate.11 
Tigecycline Evaluation and Surveillance Trial (TEST) 
was conducted to assess the global activity of MDR 
gram negative pathogens against Tigecycline between 
2004 and 2014. It was observed that Global rates of 
MDR Acinetobacter and MDR Pseudomonas 
increased from 23% and 9% respectively in 2004 to 
63% and 17% in 2014 respectively.12 
 
Materials and Methods 
This cross-sectional study was conducted in Medical 
Intensive Care Units (MICU) of Holy Family Hospital 
for a duration of 1 year after ethical approval from 
Institutional Research Forum (IRF) of Rawalpindi 
Medical University. Hospital records of patients 
admitted in MICU were included using consecutive 
sampling technique. All clinical isolates during study 
time period were included. MDR was defined as 
“Resistance to at least one agent in three or more 
antimicrobial categories.” 12 
However, only 132 were Multi Drug Resistant (MDR), 
106 (80.3%) were of MDR Acinetobacter while 
26(19.7%) were of MDR Pseudomonas. Hundred 
(75.8%) MDR isolates were obtained from catheter 
tips, 30 (22.7%) from blood while only 2(1.5%) were 
obtained from urine. Organisms that were not MDR 
Acinetobacter or MDR Pseudomonas were excluded. 
Antimicrobial resistance of included isolates was 
noted against Polymyxin E & Tigecycline. Variables 
like gender, age, organism, site of isolation and 
antimicrobial resistance against Polymyxin E & 
Tigecycline were noted. Data was entered and 
analyzed using SPSS v20. Descriptive statistics were 
applied. Mean ages of isolation of organisms were 
compared using Students “t” test. Frequencies and 
Percentages were determined for included variables. 
 
Results 
Mean age of isolation of MDR Acinetobacter was 
35.79±15.55 years while mean age of isolation of MDR 
Pseudomonas was 26.54±7.83 years. The difference 
was very highly statistically significant. (t=2.9364, 
df=130, p=0.0039) 
Fifty-eight (54.7%) isolates of MDR Acinetobacter 
were obtained from male while 48(45.3%) isolates 
were obtained from female patients. Whereas, 
14(53.8%) isolates of MDR Pseudomonas were 
obtained from male while 12(46.2%) were obtained 
from female patients. 
MDR Acinetobacter & MDR Pseudomonas were more 
commonly isolated from catheter tips, followed by 
blood. However, MDR Pseudomonas was not isolated 
from urine. (Table I) 
 
Table I Sites of isolation of MDR Acinetobacter and 
MDR Pseudomonas 
 Organism 
Site of 
Isolation 
MDR Acinetobacter 
MDR 
Pseudomonas 
 Number % Number % 
Catheter 84 79.2% 16 61.5% 
Blood 20 18.9% 10 38.5% 
Urine 2 1.9% 0 0.0% 
 
 
Table II Resistance ® and Sensitivity (S) 
percentages of MDR Acinetobacter and MDR 
Pseudomonas against Polymyxin E and Tigecycline 
Organism 
Polymyxin E Tigecycline 
R 
(%) 
S 
(%) 
R 
(%) 
S 
(%) 
MDR 
Acinetobacter 
41.5 58.5 18.9 81.1 
MDR 
Pseudomonas 
15.4 84.6 30.0 70.0 
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Table III Site wise antimicrobial resistance and 
sensitivity of MDR Acinetobacter and MDR 
Pseudomonas 
 
Discussion 
In a study conducted in India, the mean age of 
isolation of MDR Acinetobacter was 39 years while in 
a study conducted in Nigeria, it was 38.2 years which 
is close to mean age observed in our study.13,14 
According to our study, 55% of clinical isolates were 
obtained from male while 45% from female patients 
which is in accordance with studies conducted in 
Nigeria (52% male, 48% female) and Lebanon (60% 
male, 40% female).14,15 
It was also observed that maximum number of 
isolates of MDR Acinetobacter were obtained from 
catheter tips (86%) in Nigeria, and least number of 
isolates were obtained from urine (8%) in Lebanon 
which is also in accordance with observations of 
present study.14,15 
There has been a slight variation in antimicrobial 
resistance of MDR Acinetobacter against Tigecycline 
between different ends of the world. It was stated in 
studies conducted in Iran, Pakistan and Poland in 
2013, 2014 and 2016 respectively that 20%, 20% and 
18.4% clinical isolates were resistant to Tigecycline 
which is very close to the findings of present study 
where 18.9% clinical isolates of MDR Acinetobacter 
were resistant against Tigecycline.16-18 
However, in Saudia Arabia & Greece, resistance was 
reported to be 56% and 74.2% respectively in 2016 
which is high as compared to our finings19,20. The 
difference may be attributed to regional factors and 
hospital policies for administration of antibiotics. 
Similar variations have been observed in 
antimicrobial resistance of MDR Acinetobacter 
against Polymyxin E. According to our observations, 
41.5% of clinical isolates of MDR Acinetobacter were 
found to be resistant against Polymyxin E which is 
close to findings of studies conducted in Saudi Arabia 
(31%) in 2018, India (53.1%) in 2016 and Iran (48.8%) 
in 2016. 21-23 
However, the trend has been observed to be lower in 
Taiwan (10.4%) in 2012 and Greece (7.9%) in 2016 as 
compared to our study. 24,25 
In a study conducted in Italy as a part of TEST trial, it 
was observed that antimicrobial resistance of MDR 
Pseudomonas against Tigecycline was 16% from 2012 
to 2014 while according to our observations it is 
30%.26 
In a study conducted in Saudi Arabia in 2012, it was 
observed that 6% of MDR Pseudomonas were 
resistant to Polymyxin E which is less than 15.4% as 
observed in our study.27 The difference may be 
attributed to difference in time.  
The limitation of this study was that the duration of 
data collection was brief and MIC based analysis was 
not performed. For future studies, it is recommended 
that data collection duration should be increased, 
analysis should be MIC based, XDR clinical isolates 
should be included and antimicrobial resistance 
against combination therapies should be determined 
as well. 
Conclusion 
MDR Acinetobacter or MDR Pseudomonas are 
prevalent in different age groups. Both are more 
commonly isolated from male as compared to female 
patients. Catheter tips were the most common site of 
isolation followed by blood and urine. The 
antimicrobial resistance of MDR Acinetobacter or 
MDR Pseudomonas against Polymyxin E and 
Tigecycline is alarmingly high. Therefore, proper 
strategies should be formulated regarding use of 
antimicrobial agents. 
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